文献速递心脑血管急症创伤与烧伤重症综合管理与镇静镇痛

凝血酶原复合物逆转Xa因子抑制剂对创伤性脑损伤患者的影响

Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
PubMed 文献 · Neurocrit Care · 2022-05-27
一句话结论单中心回顾性队列显示,对服用阿哌沙班或利伐沙班的轻症TBI患者,用PCC逆转未能显著减少出血进展或住院死亡,也未增加血栓栓塞事件。

该单中心回顾性队列纳入2016年9月1日至2019年9月1日期间≥18岁、入院前服用阿哌沙班或利伐沙班并发生任何严重程度急性TBI的患者,按是否接受PCC逆转分为逆转组与未逆转组,排除自发性ICH或已知凝血病,采用倾向评分匹配(年龄、简明损伤定级(头部)评分、Charlson合并症指数评分)。115例符合标准者中84例进入匹配数据集;两组多数为轻度TBI(入院GCS 14–15分:逆转组35例[83.3%],未逆转组40例[95.2%])。逆转组平均接受活化PCC 34.3 U/kg、四因子PCC 30.5 U/kg或四因子PCC 54.9 U/kg联合活化PCC。结果显示出血进展发生率(未逆转组10.8% vs 逆转组15.0%,p=0.739)、ICH体积中位变化(未逆转组0 mL vs 逆转组1 mL,p=0.2199)、住院死亡(未逆转组3例[7.1%] vs 逆转组4例[9.5%],p>0.999)均无显著差异;逆转组1例住院期间发生深静脉血栓,DVT发生率差异无统计学意义(p>0.999)。

要点

  • 对服用阿哌沙班或利伐沙班的轻症TBI患者,PCC逆转组与未逆转组的出血进展发生率无显著差异(未逆转组10.8% vs 逆转组15.0%,p=0.739)。
  • 两组ICH体积中位变化无显著差异(未逆转组0 mL vs 逆转组1 mL,p=0.2199)。
  • 住院死亡无显著差异(未逆转组3例[7.1%] vs 逆转组4例[9.5%],p>0.999)。
  • 逆转组1例住院期间发生深静脉血栓,DVT发生率差异无统计学意义(p>0.999)。
  • 逆转组平均剂量为活化PCC 34.3 U/kg、四因子PCC 30.5 U/kg或四因子PCC 54.9 U/kg联合活化PCC。

适用人群与场景

  • ≥18岁、2016年9月1日至2019年9月1日期间入院、入院前服用阿哌沙班或利伐沙班、发生任何严重程度急性TBI的患者;排除自发性ICH或已知凝血病患者。

处置流程与药物剂量

  • 逆转组患者平均接受活化PCC 34.3 U/kg、四因子PCC 30.5 U/kg或四因子PCC 54.9 U/kg联合活化PCC。

研究设计与关键结果

  • 单中心回顾性队列,115例符合纳入标准,84例进入倾向评分匹配数据集(匹配变量:年龄、简明损伤定级(头部)评分、Charlson合并症指数评分),两组基线特征、合并症及TBI严重程度相似。
  • 多数患者为轻度TBI(入院GCS 14–15分):逆转组35例(83.3%),未逆转组40例(95.2%)。
  • 主要终点出血稳定(48小时内):出血进展发生率未逆转组10.8% vs 逆转组15.0%,p=0.739,无显著差异。
  • 次要终点:ICH体积中位变化未逆转组0 mL vs 逆转组1 mL,p=0.2199,无显著差异。
  • 住院死亡:未逆转组3例(7.1%) vs 逆转组4例(9.5%),p>0.999,无显著差异。
  • 血栓栓塞事件:逆转组1例住院期间发生深静脉血栓,DVT发生率差异无统计学意义(p>0.999)。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,PCC用于治疗与轻度TBI相关的Xa因子抑制剂相关ICH,未显著影响出血进展的发生率或程度,且PCC治疗未导致血栓栓塞事件增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Anticoagulant use prior to trauma has been associated with increased incidence of traumatic brain injury (TBI), intracranial hemorrhage (ICH) progression, and mortality. Prothrombin complex concentrates (PCCs) are commonly used as off-label treatments for factor Xa inhibitor-associated life-threatening hemorrhage. At this time, there is no consensus regarding appropriate indication, target dose, or outcomes of PCC administration in patients presenting with traumatic ICH. This study seeks to evaluate the impact of reversal with PCC on hemorrhage progression and outcomes in patients with TBI on preinjury factor Xa inhibitors.

METHODS: This single-center retrospective cohort study included patients ≥ 18 years presenting with an acute TBI of any severity on apixaban or rivaroxaban from September 1, 2016, to September 1, 2019. Patients were grouped on the basis of receipt of PCCs for reversal (i.e., reversal or no reversal). Exclusion criteria included spontaneous ICH or known coagulopathy. Propensity score matching was conducted with the following variables: age, Abbreviated Injury Scale (head) score, and Charlson Comorbidity Index score. The primary outcome was hemorrhage stability within 48 h. Secondary outcomes included degree of hemorrhage progression, in-hospital mortality, discharge disposition, and incidence of thromboembolic events.

RESULTS: Of the 115 patients meeting inclusion criteria, 84 were included in the propensity score matched data set. Baseline characteristics, comorbidities, and TBI severity were similar. The majority of patients in the reversal group (35 [83.3%]) and the no reversal (NR) group (40 [95.2%]) experienced a mild TBI (admission Glasgow Coma Scale score of 14 to 15). In the reversal group, patients received 34.3 units/kg activated PCC, 30.5 units/kg four-factor PCC, or 54.9 units/kg four-factor PCC and activated PCC on average. There was no difference observed in the incidence of hemorrhage progression (10.8% NR vs. 15.0% reversal; p = 0.739) or in median change in ICH volume (0 mL NR vs. 1 mL reversal; p = 0.2199) between groups. Additionally, reversal did not affect in-hospital mortality (3 [7.1%] NR vs. 4 [9.5%] reversal; p > 0.999). One patient in the reversal group developed a deep vein thrombosis (DVT) during the hospitalization; however, this did not result in a statistically significant difference in the occurrence of DVT (p > 0.999).

CONCLUSIONS: This study demonstrated that PCC used for the treatment of factor Xa inhibitor-associated ICH related to mild TBI did not significantly impact the incidence or degree of hemorrhage progression, and PCC treatment did not result in increased thromboembolic events.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Cooksey GE, Hamilton LA, McMillen JC, et al. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries. Neurocrit Care. 2022. PMID: 35624388. doi:10.1007/s12028-022-01521-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。